More than 50% of prescriptions is written for people aged 65 years and older. Many older people suffer from comorbid conditions and one in three takes at least five drugs or more on a daily basis. This significantly increases the risk of Adverse Drug Events (ADEs) and hospitalization. Up to one third of emergency admissions in elderly people is drug-related. There remains a lack of clinical data to support prescription decisions as relatively few medicines have been clinically evaluated in age-appropriate patients. In addition, many drugs are not available in formulations that are suitable for the elderly, leading to non-compliance and lack of therapeutic efficacy. In 2011, the EMA introduced its Geriatric Medicines Strategy to ensure that the medical requirements of older people are identified earlier in the drug development process. In 2012, the ICH E7 guidelines were revised to include a greater focus on involving more geriatric patients in drug trials. View Full Report With Complete TOC at http://www.researchmoz.us/geriatric-medicine-development-carving-out-new-opportunities-to-treat-age-related-diseases-report.html

1. Geriatric Medicine Development - Carving out New Opportunities to Treat Age-related Diseases
More than 50% of prescriptions is written for people aged 65 years and older. Many older people suffer from comorbid conditions and one in three takes at least
five drugs or more on a daily basis. This significantly increases the risk of Adverse Drug Events (ADEs) and hospitalization. Up to one third of emergency
admissions in elderly people is drug-related.
There remains a lack of clinical data to support prescription decisions as relatively few medicines have been clinically evaluated in age-appropriate patients. In
addition, many drugs are not available in formulations that are suitable for the elderly, leading to non-compliance and lack of therapeutic efficacy. In 2011, the
EMA introduced its Geriatric Medicines Strategy to ensure that the medical requirements of older people are identified earlier in the drug development process.
In 2012, the ICH E7 guidelines were revised to include a greater focus on involving more geriatric patients in drug trials.
Scope
Reviews the current regulatory landscape and helps sponsors to understand the potential impact of recent guidelines. Assesses the barriers to entry in geriatric
medicines and identifies potential ways to overcome them and improve clinical decision making. Evaluates the importance of establishing Target Quality Product
Profiles (TQPP) to help sponsors determine the target patient population earlier on in drug development. Identifies treatment gaps and commercial opportunities
based on primary care real-time data and KOL insights. Analyses different strategies to develop age-appropriate medicines in niche therapeutic fields and
discusses methods to encourage the smarter prescription of medicines.
Key Reasons to Purchase
Utilize the insights from this study to analyze the barriers facing the geriatrics market Understand the impact of drug development in this market now and in the
future Find out why regulators are paying more attention to unnecessary “exclusion criteria” and encouraging the inclusion of older people to
ensure trials are age-appropriate and more representative of the real world setting. Assess the opportunities available for companies to develop age-appropriate
dosages and formulations for existing drug classes that are currently widely associated with ADEs in the elderly as well as new therapeutic prospects.
table Of Content
executive Summary
methodology
geriatric Medicines: An Overview
emerging Issues
unmet Clinical Needs
current Landscape
regulatory Environment
political Will For Change
strategic Considerations For Developing Geriatric Medicines
barriers To Developing Geriatric Drugs
clinical Trial Considerations
“big Data’s” Role In Identifying Treatment Gaps And Commercial Opportunities
raising Physician And Patient Awareness
commercial Opportunities To Address The Treatment Gap
improving Existing Therapies
new Therapeutic Opportunities
appendix
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Geriatric Medicine Development - Carving out New Opportunities to Treat Age-related Diseases